Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects
Open Access
- 1 January 2012
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Virology
- Vol. 1 (1), 23-30
- https://doi.org/10.5501/wjv.v1.i1.23
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) infection is the leading cause of economic casualty in swine industry worldwide. The virus can cause reproductive failure, respiratory disease, and growth retardation in the pigs. This review deals with current status of commercial PRRS vaccines presently used to control PRRS. The review focuses on the immunogenicity, protective efficacy and safety aspects of the vaccines. Commercial PRRS modified-live virus (MLV) vaccine elicits delayed humoral and cell-mediated immune responses following vaccination. The vaccine confers late but effective protection against genetically homologous PRRSV, and partial protection against genetically heterologous virus. The MLV vaccine is of concern for its safety as the vaccine virus can revert to virulence and cause diseases. PRRS killed virus (KV) vaccine, on the other hand, is safe but confers limited protection against either homologous or heterologous virus. The KV vaccine yet helps reduce disease severity when administered to the PRRSV-infected pigs. Although efforts have been made to improve the immunogenicity, efficacy and safety of PRRS vaccines, a better vaccine is still needed in order to protect against PRRSV.Keywords
This publication has 72 references indexed in Scilit:
- Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus, AsiaEmerging Infectious Diseases, 2011
- The assessment of efficacy of porcine reproductive respiratory syndrome virus inactivated vaccine based on the viral quantity and inactivation methodsVirology Journal, 2011
- Immune Evasion of Porcine Reproductive and Respiratory Syndrome Virus through Glycan Shielding Involves both Glycoprotein 5 as Well as Glycoprotein 3Journal of Virology, 2011
- Porcine Reproductive and Respiratory Syndrome Virus Inhibits Type I Interferon Signaling by Blocking STAT1/STAT2 Nuclear TranslocationJournal of Virology, 2010
- Immunogenicity of recombinant GP5 protein of porcine reproductive and respiratory syndrome virus expressed in tobacco plantVeterinary Immunology and Immunopathology, 2010
- Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthraxProceedings of the National Academy of Sciences, 2010
- Induction of inducible CD4+CD25+Foxp3+ regulatory T lymphocytes by porcine reproductive and respiratory syndrome virus (PRRSV)Veterinary Immunology and Immunopathology, 2010
- Adjuvants for porcine reproductive and respiratory syndrome virus vaccinesVeterinary Immunology and Immunopathology, 2009
- Influence of N-Linked Glycosylation of Porcine Reproductive and Respiratory Syndrome Virus GP5 on Virus Infectivity, Antigenicity, and Ability To Induce Neutralizing AntibodiesJournal of Virology, 2006
- Oral immunization induces local and distant mucosal immunity in swineVeterinary Immunology and Immunopathology, 2004